AIDS

Skip Navigation LinksHome > July 17, 2009 - Volume 23 - Issue 11 > Immunological success is predicted by enfuvirtide but not in...
AIDS:
doi: 10.1097/QAD.0b013e32832cdc26
Clinical Science: Concise Communication

Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients

Viard, Jean-Paula; Fagard, Catherineb; Chaix, Marie-Laurea; Rouzioux, Christinea; Bouteloup, Vincentb; Bentata, Michellec; de Verdière, Nathalie Colind; Pahlavan, Golrize; Weiss, Laurencef; Lévy, Yvesg; Chêne, Genevièveb; for the ANRS 123 ETOILE trial group

Collapse Box

Abstract

Objectives: To evaluate the efficacy of adding interleukin-2 (IL-2) to an optimized background treatment in HIV-1 patients with advanced failure.

Design: Randomized, open-label, multicentre controlled trial.

Methods: Patients with CD4 T-cell count of less than 200 cells/μl, plasma HIV-1 RNA of more than 10 000 copies/ml and a genotypic sensitivity score showing two or less active drugs were randomized to either eight IL-2 cycles with optimized background treatment or optimized background treatment alone. Optimization was made according to genotypic sensitivity score. Enfuvirtide was added in enfuvirtide-naive patients. Evaluation was performed at week 52 on the proportions of patients with CD4 cell count of at least 200 cells/μl (primary outcome), of patients with a CD4 cell count increase of at least 50 cells/μl from week 0, on plasma HIV-1 RNA and HIV-related events.

Results: Fifty-six patients were analysed. Median age was 43 years, 61% were at Center for Disease Control and Prevention stage C, 43% had a genotypic sensitivity score of 0, median baseline CD4 cell count and plasma HIV-1 RNA values were 64 cells/μl and 4.9 log10 copies/ml, respectively. Treatment could be optimized in 23 patients. At week 52, in the IL-2 and control groups, the proportion of patients with CD4 cell count of at least 200 cells/μl (14 and 18%) or a CD4 cell count increase of at least 50 cells/μl (25 and 32%) and median plasma HIV-1 RNA were not significantly different. In multivariate analysis, optimization with enfuvirtide and baseline CD4 cell count were statistically associated with CD4 cell count of at least 200 cells/μl at week 52 (P = 0.003 and P = 0.01). Optimization with enfuvirtide was the only factor associated with a CD4 cell count gain of at least 50 cells/μl (P < 0.001). There was no difference in the rate of AIDS events between groups.

Conclusion: IL-2 failed to increase CD4 cell count in immunocompromised patients with multiple therapeutic failures. Enfuvirtide use was highly associated with success.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.